Fortress Biotech, Inc. (FBIO) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 196.58M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $196.58M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $255.84M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $79.38M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $86.22M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $74.39M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $91.34M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $57.26M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $58.85M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $76.20M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $83.77M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $80.93M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $72.31M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $78.02M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $152.48M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $178.27M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $208.35M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $248.77M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $287.51M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $305.74M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $252.72M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $274.99M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $289.90M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $233.35M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $218.39M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $183.28M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $135.94M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $136.86M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $134.94M | (m) | (m) |
| 2019-06-30 | (m) | (m) | $149.41M | (m) | (m) |
| 2019-03-31 | (m) | (m) | $116.44M | (m) | (m) |
| 2018-12-31 | (m) | (m) | $65.51M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $95.87M | (m) | (m) |
| 2018-06-30 | (m) | (m) | $98.59M | (m) | (m) |
| 2018-03-31 | (m) | (m) | $124.02M | (m) | (m) |
| 2017-12-31 | (m) | (m) | $113.92M | (m) | (m) |
| 2017-09-30 | (m) | (m) | $110.54M | (m) | (m) |
| 2017-06-30 | (m) | (m) | $144.34M | (m) | (m) |
| 2017-03-31 | (m) | (m) | $134.04M | (m) | (m) |
| 2016-12-31 | (m) | (m) | $88.29M | (m) | (m) |
| 2016-09-30 | (m) | (m) | $82.54M | (m) | (m) |
| 2016-06-30 | (m) | (m) | $71.34M | (m) | (m) |
| 2016-03-31 | (m) | (m) | $81.42M | (m) | (m) |
| 2015-12-31 | $98.18M | (m) | $98.18M | $0.00 | (m) |
| 2015-09-30 | $65.51M | (m) | $25.56M | $39.95M | (m) |
| 2015-06-30 | $61.04M | (m) | $41.04M | $20.00M | (m) |
| 2015-03-31 | $68.93M | (m) | $48.93M | $20.00M | (m) |
| 2014-12-31 | $69.76M | (m) | $49.76M | $20.00M | (m) |
| 2014-09-30 | (m) | (m) | $71.59M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $75.80M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $79.98M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $99.52M | (m) | (m) |
| 2013-09-30 | (m) | (m) | $106.27M | (m) | (m) |
| 2013-06-30 | (m) | (m) | $67.89M | (m) | (m) |
| 2013-03-31 | (m) | (m) | $44.05M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $40.20M | (m) | (m) |
| 2012-09-30 | (m) | (m) | $47.48M | (m) | (m) |
| 2012-06-30 | (m) | (m) | $38.21M | (m) | (m) |
| 2012-03-31 | (m) | (m) | $17.73M | (m) | (m) |
| 2011-12-31 | (m) | (m) | $23.16M | (m) | (m) |
| 2011-09-30 | (m) | (m) | $26.71M | (m) | (m) |
| 2011-06-30 | (m) | (m) | $29.65M | (m) | (m) |
| 2011-03-31 | (m) | (m) | $9.27M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $14.86M | (m) | (m) |
| 2010-09-30 | (m) | (m) | $15.78M | (m) | (m) |
| 2009-12-31 | (m) | (m) | $1.51M | (m) | (m) |
| 2008-12-31 | (m) | (m) | $7.00K | (m) | (m) |
| 2006-06-27 | (m) | (m) | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |